In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole

Drug Metabolism and Disposition

Volumn 39, Issue 5, 2011, Pages 847-857

  Lundahl, Anna ^a   Hedeland, Mikael ^a   Bondesson, Ulf ^a   Lennernäs, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; KETOCONAZOLE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; FEMORAL VEIN; HEPATIC VEIN; IN VIVO STUDY; INTESTINE ABSORPTION; JEJUNUM; LIVER METABOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PORTAL VEIN; PRIORITY JOURNAL; SWINE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINARY EXCRETION;

14-ALPHA DEMETHYLASE INHIBITORS; 5-ALPHA REDUCTASE INHIBITORS; ANIMALS; BILE; DRUG INTERACTIONS; FINASTERIDE; HALF-LIFE; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; KETOCONAZOLE; LIVER; MALE; PROSTATIC NEOPLASMS; SWINE;

SUIDAE;

EID: 79954996910     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.035311     Document Type: Article

References (43)

1. Achour B, Rostami-Hodjegan A, and Barber J (2010) Assessing abundance of cytochrome P450 enzymes using mass spectrometry based methods: Analysis of porcine liver (Poster), in Drug Metabolism Discussion Group Meeting; 2010 Sept 15-17; Canterbury, UK. DMDG, Thurmaston, Leicester, England.
2. Amidon GL, Lennernäs H, Shah VP, and Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
3. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, et al. (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192-1202.
4. Bader A, Hansen T, Kirchner G, Allmeling C, Haverich A, and Borlak JT (2000) Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions. Br J Pharmacol 129: 331-342. (Pubitemid 30072654)
5. Bergman E, Lundahl A, Fridblom P, Hedeland M, Bondesson U, Knutson L, and Lennernäs H (2009) Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. Drug Metab Dispos 37:2349-2358.
6. Carlin JR, Christofalo P, Arison BH, Ellsworth RE, Rosegay A, Miller RR, Chiu SH, and VandenHeuvel WJ (1997) Disposition and metabolism of finasteride in dogs. Drug Metab Dispos 25:100-109. (Pubitemid 27045140)
7. 14C]finasteride after oral administration in humans. Drug Metab Dispos 20:148-155.
8. Drake L, Hordinsky M, Fiedler V, Swinehart J, Unger WP, Cotterill PC, Thiboutot DM, Lowe N, Jacobson C, Whiting D, et al. (1999) The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol 41:550-554. (Pubitemid 29480402)
9. Fang J, McKay G, Hubbard JW, Hawes EM, and Midha KK (2000) Dose staggering as a strategy to reduce drug- drug interactions due to reversible enzyme inhibition between orally administered drugs with high first pass effect: A computer simulation study. Biopharm Drug Dispos 21:249-259. (Pubitemid 32747115)
10. Hijazi Y and Boulieu R (2002) Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 30:853-858. (Pubitemid 34671099)
11. Huskey SW, Dean DC, Miller RR, Rasmusson GH, and Chiu SH (1995) Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab Dispos 23:1126-1135.
12. Ishii Y, Mukoyama H, and Ohtawa M (1994) In vitro biotransformation of finasteride in rat hepatic microsomes: Isolation and characterization of metabolites. Drug Metab Dispos 22: 79-84. (Pubitemid 24045384)
13. Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, Ballentine Carter H, Costantino JP, Epstein JI, Godley PA, et al. (2009) Use of 5-α-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline [published erratum appears in J Clin Oncol 27:2742, 2009].
14. J Clin Oncol 27:1502-1516.
15. Lampen A, Christians U, Gonschior AK, Bader A, Hackbarth I, von Engelhardt W, and Sewing KF (1996) Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. Br J Pharmacol 117:1730-1734. (Pubitemid 26121618)
16. Loftsson T and Hreinsdóttir D (2006) Determination of aqueous solubility by heating and equilibration: A technical note. AAPS PharmSciTech 7:E4.
17. Lundahl A, Hedeland M, Bondesson U, Knutson L, and Lennernäs H (2009a) The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men. Eur J Pharm Sci 36:433-443.
18. Lundahl A, Lennernäs H, Knutson L, Bondesson U, and Hedeland M (2009b) Identification of finasteride metabolites in human bile and urine by high-performance liquid chromatography/ tandem mass spectrometry. Drug Metab Dispos 37:2008-2017.
19. Nagashima A, Tanaka E, Inomata S, Honda K, and Misawa S (2005) A study of the in vitro interaction between lidocaine and premedications using human liver microsomes. J Clin Pharm Ther 30:185-188. (Pubitemid 41583615)
20. Nissen PH, Winterø AK, and Fredholm M (1998) Mapping of porcine genes belonging to two different cytochrome P450 subfamilies. Anim Genet 29:7-11. (Pubitemid 28329398)
21. Nordgren A, Karlsson T, and Wiklund L (2002) Glutamine concentration and tissue exchange with intravenously administered alpha-ketoglutaric acid and ammonium: A dose-response study in the pig. Nutrition 18:496-504. (Pubitemid 34586805)
22. Ohtawa M, Morikawa H, and Shimazaki J (1991) Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5α- androst-1-ene-17β-carboxamide, a new type of specific competitive inhibitor of testosterone 5α-reductase, in volunteers. Eur J. Drug Metab Pharmacokinet 16:15-21.
23. Olsen AK, Hansen KT, and Friis C (1997) Pig hepatocytes as an in vitro model to study the regulation of human CYP3A4: Prediction of drug-drug interactions with 17 alphaethynylestradiol. Chem Biol Interact 107:93-108. (Pubitemid 27509003)
24. Petri N, Bergman E, Forsell P, Hedeland M, Bondesson U, Knutson L, and Lennernäs H (2006) First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. Drug Metab Dispos 34:1182-1189.
25. Perdaems N, Blasco H, Vinson C, Chenel M, Whalley S, Cazade F, and Bouzom F (2010) Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin Pharmacokinet 49:239-258.
26. Rittmaster RS, Stoner E, Thompson DL, Nance D, and Lasseter KC (1989) Effect of MK-906, a specific 5α-reductase inhibitor, on serum androgens and androgen conjugates in normal men. J Androl 10:259-262. (Pubitemid 19206758)
27. Rowland Yeo K, Jamei M, Yang J, Tucker GT, and Rostami-Hodjegan A (2010) Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci 39:298-309.
28. Rubin GM and Tozer TN (1986) Hepatic binding and Michaelis-Menten metabolism of drugs. J Pharm Sci 75:660-663. (Pubitemid 16038894)
29. Sakuma T, Shimojima T, Miwa K, and Kamataki T (2004) Cloning CYP2D21 and CYP3A22 cDNAs from liver of miniature pigs. Drug Metab Dispos 32:376-378. (Pubitemid 38420269)
30. Sano N, Nio M, Ishii T, Amae S, Wada M, Nishi K, Endo N, Hayashi Y, and Ohi R (2002) Oral FK 506 blood levels are elevated in pig short bowel model: Further investigations with co-administration of an intestinal CYP3A4 inhibitor. Transplant Proc 34:1050-1051. (Pubitemid 34556920)
31. Sjödin E, Fritsch H, Eriksson UG, Logren U, Nordgren A, Forsell P, Knutson L, and Lennernäs H (2008) Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs. Drug Metab Dispos 36:1519-1528.
32. Skaanild MT and Friis C (1997) Characterization of the P450 system in Gottingen minipigs. Pharmacol Toxicol 80 (Suppl 2):28-33.
33. Steiner JF (1996) Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet 30:16-27. (Pubitemid 26030418)
34. Sudduth SL and Koronkowski MJ (1993) Finasteride: The first 5 α-reductase inhibitor. Pharmacotherapy 13:309-329.
35. Suzuki R, Satoh H, Ohtani H, Hori S, and Sawada Y (2010) Saturable binding of finasteride to steroid 5α-reductase as determinant of nonlinear pharmacokinetics. Drug Metab Pharmacokinet 25:208-213.
36. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, et al. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215-224. (Pubitemid 36859473)
37. Thörn HA, Hedeland M, Bondesson U, Knutson L, Yasin M, Dickinson P, and Lennernäs H (2009) Different effects of ketoconazole on the stereoselective first-pass metabolism of R/S-verapamil in the intestine and the liver: Important for the mechanistic understanding of first-pass drug-drug interactions. Drug Metab Dispos 37:2186-2196.
38. Vertzoni MV, Reppas C, and Archontaki HA (2006) Optimization and validation of a highperformance liquid chromatographic method with UV detection for the determination of ketoconazole in canine plasma. J Chromatogr B Analyt Technol Biomed Life Sci 839:62-67. (Pubitemid 44037521)
39. Winchell GA, Gregoire S, Taylor AM, Hegland J, and Hunninghake DB (1993) Finasteride, a steroid 5α-reductase inhibitor, does not affect the oxidative metabolism of antipyrine. J Clin Pharmacol 33:967-970. (Pubitemid 23304651)
40. Wong A and Bandiera SM (1998) Induction of hepatic cytochrome P450 2B and P450 3A isozymes in rats by zolazepam, a constituent of Telazol. Biochem Pharmacol 55:201-207. (Pubitemid 28006187)
41. Wu CY and Benet LZ (2005) Predicting drug disposition via application of BCS: Transport/ absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23. (Pubitemid 40558141)
42. Yang J, Kjellsson M, Rostami-Hodjegan A, and Tucker GT (2003) The effects of dose staggering on metabolic drug-drug interactions. Eur J Pharm Sci 20:223-232. (Pubitemid 37205216)
43. Zhang X, Quinney SK, Gorski JC, Jones DR, and Hall SD (2009) Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab Dispos 37:1587-1597.